Word: pfizer
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...didn't know we've been in a bull market for six years. It's true. Despite the burst bubble, most stocks are up 75% or more since the end of 1999. They're probably not the ones you own, though. Big-name companies like GE, Pfizer and Microsoft--which investors and mutual-fund managers tend to gravitate to--have been flailing since the bust. That's why the popular market gauges that those stocks dominate (Dow Jones industrial average, Standard & Poor's 500) still languish below their old highs. Yet the time may have come to stock...
...approved the first inhalable insulin, Pfizer's Exubera. Experts hope the user-friendly alternative to injections will get more diabetics to use insulin to help manage blood sugar and prevent complications...
...Pfizer's move is a dramatic one, but it's also an important one-and not just for Big Pharma's balance sheets. In the wake of the Vioxx withdrawal, many arthritis sufferers have turned to drugs in the ibuprofen and naproxen families, such as Advil and Aleve. But earlier this year the Food and Drug Administration (FDA) announced that those drugs may also carry cardiovascular risks; in any event, for some people they just don't pack the same pain-relieving punch. Others patients are relying on oxycontin and morphine-based medications, which may not endanger the cardiovascular system...
...major question raised by such a comparatively high-stakes trial is, Why use such high-risk patients? The last thing people who are already in precarious cardiovascular health need-or so it would seem-is to begin taking a drug that could endanger them even further. Pfizer - not to mention the patients themselves-is apparently banking on the belief that Celebrex simply isn?t that risky, and that any slight dangers are outweighed by the benefits. ?Pfizer is fulfilling the commitment it made over a year ago to study Celebrex in this patient population," says Pfizer spokesman Bryant Haskins. When...
...risk," said Nissen, who served on an FDA panel which last February recommended just such a study. "We will have 10 times the statistical power of any study ever done of these drugs." The results may thus indeed finally answer any lingering questions about how safe Celebrex is, something Pfizer no doubt hopes-but also fears...